AMRXHealthcareMid-Cap
Amneal Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Amneal Pharmaceuticals, Inc. (AMRX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are AMRX insiders buying or selling?
Amneal Pharmaceuticals, Inc. insiders reported 22 open-market buys ($13.0M) and 41 sells ($927.0M) across 63 Form 4 filings — a net selling position of $914.0M.
Source: SEC EDGAR Form 4
Key Statistics (as of May 12, 2026)
Total Form 4 filings
63
SEC EDGAR
Insider filers
23
Insider buys (22)
$13.0M
Insider sells (41)
$927.0M
Insider sentiment
Net sellingNet insider flow of $914.0M in net selling.
Recent AMRX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 12, 2026 | Deborah M. Autor | Director | Sale | 34.8K | $12.94 | $450.6K |
| Nov 19, 2025 | Ted C Nark | Director | Sale | 50.0K | $11.72 | $586.0K |
| Nov 14, 2025 | Nikita Shah | Executive Vice President | Sale | 131.9K | $11.92 | $1.6M |
| Aug 28, 2025 | John Kiely | Director | Sale | 32.0K | $9.23 | $295.4K |
| Aug 25, 2025 | Nikita Shah | Executive Vice President | Sale | 120.8K | $9.65 | $1.2M |
| Aug 22, 2025 | Andrew S Boyer | Executive Vice President | Sale | 279.2K | $9.38 | $2.6M |
| Aug 15, 2025 | Nikita Shah | Executive Vice President | Sale | 71.7K | $9.29 | $666.0K |
| Aug 13, 2025 | Nikita Shah | Executive Vice President | Sale | 50.0K | $9.04 | $452.0K |
| Aug 13, 2025 | Jason B. Daly | EVP, Chief Legal Officer | Sale | 22.0K | $9.05 | $199.1K |
| Aug 13, 2025 | Andrew S Boyer | Executive Vice President | Sale | 33.4K | $9.05 | $302.6K |
| Jun 18, 2025 | Patel Gautam | Director | Sale | 94.9K | $8.02 | $761.1K |
| Jun 12, 2025 | Patel Gautam | Director | Sale | 56.4K | $8.02 | $452.5K |
| May 19, 2025 | Nikita Shah | Executive Vice President | Sale | 49.1K | $7.58 | $372.5K |
| May 13, 2025 | John Kiely | Director | Sale | 50.0K | $7.59 | $379.5K |
| May 6, 2025 | Patel Gautam | Director | Sale | 8.7K | $8.00 | $69.3K |
| Apr 2, 2025 | Patel Gautam | Director | Sale | 80.0K | $8.30 | $664.0K |
| Mar 17, 2025 | Patel Tushar Bhikhubhai | 10% Owner | Sale | 5.0M | $8.35 | $41.8M |
| Mar 7, 2025 | Andrew S Boyer | Executive Vice President | Sale | 125.0K | $8.89 | $1.1M |
| Mar 7, 2025 | Jason B. Daly | EVP, Chief Legal Officer | Sale | 90.0K | $8.80 | $792.2K |
| Mar 7, 2025 | Tasos Konidaris | Executive Vice President & CFO | Sale | 100.0K | $8.91 | $891.0K |
| Mar 7, 2025 | Emily Peterson Alva | Director | Sale | 80.0K | $8.90 | $712.0K |
| Mar 6, 2025 | Patel Gautam | Director | Sale | 80.0K | $8.90 | $712.0K |
| Feb 5, 2025 | Patel Gautam | Director | Sale | 80.0K | $8.14 | $651.2K |
| Jan 10, 2025 | Patel Gautam | Director | Sale | 62.6K | $8.01 | $501.3K |
| Jan 6, 2025 | Patel Gautam | Director | Sale | 17.4K | $8.01 | $139.5K |
Showing the 25 most recent of 63 Form 4 filings for Amneal Pharmaceuticals, Inc..
Most active AMRX insiders
- Patel Gautam10 filings
- Nikita Shah9 filings
- Andrew S Boyer7 filings
- Jason B. Daly4 filings
- John Kiely4 filings
Ask anything about AMRX insider activity
Use Trabud's AI agent to query Amneal Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me AMRX CEO purchases this year" or compare it against any other ticker.
Open the AI agentAMRX insider trading FAQ
Are Amneal Pharmaceuticals, Inc. insiders buying or selling?
Across 63 SEC Form 4 filings, Amneal Pharmaceuticals, Inc. (AMRX) insiders reported 22 open-market purchases totaling $13.0M and 41 sales totaling $927.0M. That is a net selling position of $914.0M.
How many insiders trade AMRX stock?
23 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Amneal Pharmaceuticals, Inc.. The most recent filing was accepted on May 12, 2026.
Where does Trabud get AMRX insider trading data?
All AMRX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.